Jacob Irwin
About Jacob Irwin
Jacob Irwin serves as the Director of Process Development at BridgeBio, where he oversees AAV-based gene therapies. He holds a PhD in Chemical Engineering from the University of Virginia and has over 13 years of experience in the biopharmaceutical field.
Work at BridgeBio
Jacob Irwin has been serving as the Director of Process Development at BridgeBio since 2022. In this role, he oversees both upstream and downstream process development functions, specifically focusing on AAV-based gene therapies. His responsibilities include designing, executing, and analyzing experiments to enhance the efficiency and effectiveness of biopharmaceutical processes. Prior to his current position, he held the role of Associate Director of Process Development at BridgeBio for six months in 2021.
Education and Expertise
Jacob Irwin holds a Master of Science (MS) in Chemical Engineering from the University of Virginia, where he studied from 2010 to 2012. He also earned a Doctor of Philosophy (PhD) in Chemical Engineering from the same institution, completing his studies from 2010 to 2014. His undergraduate education includes a Bachelor of Science (B.S.) in Biological Engineering and a minor in Spanish from the University of Arkansas, where he studied from 2004 to 2008. His educational background supports his expertise in chemical and biomolecular engineering.
Background
Jacob Irwin has over 13 years of combined experience in industrial, academic, and entrepreneurial settings within the field of chemical and biomolecular engineering. His career includes significant roles at various organizations, including KBI Biopharma, where he worked as a Senior Scientist in Downstream/Purification Process Development, and Merck & Co., Inc., where he held multiple engineering and analyst positions. His academic experience includes serving as a Graduate Research and Teaching Assistant at the University of Virginia.
Previous Positions
Before joining BridgeBio, Jacob Irwin held several key positions that contributed to his expertise in process development. He worked as a Senior Scientist in Downstream Process Development at BridgeBio from 2019 to 2021. Prior to that, he was employed at KBI Biopharma as a Scientist II and later as a Senior Scientist from 2014 to 2019. His early career included various roles at Merck & Co., Inc., where he participated in the Global Vaccine Technology & Engineering program.
Research and Development Experience
Jacob Irwin has a strong background in independently designing, executing, and analyzing experiments in the biopharmaceutical field. His experience encompasses both upstream and downstream process development, particularly in the context of gene therapies. His work has involved extensive research and development activities, contributing to advancements in biopharmaceutical processes and technologies.